Regeneus’ newly-appointed CEO Leo Lee discusses strategic plans for growth
Leo Lee, the newly-appointed CEO of Regeneus Ltd (ASX:RGS), speaks to Proactive Investors about the Australian clinical-stage regenerative medicine company’s operations, and the wider scientific field.
The company holds a number of patents, and is focusing on global expansion, as it advances treatments in the areas of osteoarthritis, cancer, and dermatology.
Watch Leo’s full interview with Proactive Investors here.